|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These include gene fusions in vascular neoplasms (FOSB, CAMTA1 and TFE3), round cell sarcomas (BCOR, DUX4 and WT1), and fibroblastic/myofibroblastic tumors (STAT6, ALK and Pan-TRK); amplifications in well-differentiated and dedifferentiated liposarcomas (MDM2 and CDK4); and deletions in several aggressive neoplasms (SMARCB1 and SMARCA4).
|
30382607 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Material from the needle biopsy was insufficient for CGP but that case was positive with the DUX4 immunohistochemical stain as were the 2 CIC-DUX4 tumors.
|
29901569 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
After RT-PCR, the tumor sample was positive for the CIC-DUX4 fusion.
|
28062084 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As for small round cell sarcomas, novel fusion genes such as CIC-DUX4 and BCOR-CCNB3 have been identified in these tumor groups.
|
28759137 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Due to partial morphologic and immunohistochemical overlap with Ewing sarcoma, CIC-DUX4 positive tumors have generally been considered as Ewing-like sarcomas and managed similarly.
|
27919577 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
DUX4 immunohistochemistry exhibited diffuse, crisp, strong nuclear staining in all CIC-DUX4 fusion-positive round cell tumors (5/5, 100% sensitivity), and exhibited negative staining in nuclei of all of the other tested round cell tumors, including 20 Ewing sarcomas, 1 Ewing-like sarcoma, 11 alveolar rhabdomyosarcomas, 9 embryonal rhabdomyosarcomas, 12 synovial sarcomas, 7 desmoplastic small round cell tumors, 3 malignant rhabdoid tumors, 9 neuroblastomas, and 4 clear cell sarcomas (0/76, 100% specificity).
|
27879517 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene-expression profiles of CDS and eMC revealed upregulation of CIC-DUX4 downstream genes such as PEA3 family genes, <i>Ccnd2, Crh</i>, and <i>Zic1</i> IHC analyses for both mouse and human tumors showed that CCND2 and MUC5AC are reliable biomarkers to distinguish CDS from ES.
|
28404587 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CIC-DUX4 gene fusion, resulting from either a t(4;19) or t(10;19) translocation, is the most common genetic abnormality detected in EWSR1-negative small blue round cell tumors.
|
28346326 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Based on an initial observation that CIC-DUX4-positive tumors show nuclear immunoreactivity for WT1 and ETS transcription factors, FLI1 and ERG, we performed a detailed immunohistochemical and molecular analysis including these markers, to further investigate the relationship between CIC-DUX4 tumors and ES.
|
24723486 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One CIC-DUX4-positive tumor showed membranous CD99 positivity, 2 showed focal S100 positivity, and 1 showed focal CD57 positivity.
|
21813156 |
2012 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The involvement of the DUX4 region might represent the genetic hallmark of a novel subclass of small round cell tumors.
|
19837262 |
2009 |